北京招聘

Job Description (Purpose and Responsibilities)

1. Lead a team of pharmacokinetics scientists to provide high quality data, interpretation, insight and reports to the drug discovery projects in a timely manner to enable effective project decision making;
2. Ensure the capability meet the annual business, research and organizational development objectives set by the discovery project unit;
3. Provide input to the study designs for in vivo non-GLP and GLP pharmacology and toxicology studies; provide specific scientific and technical input to projects where needed, eg, act as study director or principal investigator responsible for externally conducted PK, TK and ADME (as needed) studies as appropriate; ensure seamless and timely transfer of bioanalytical and ADA data to the Preclinical PK/PD team;  
4. Ensure the capability operations meeting the safety and relevant regulations (eg, SOPs and GLP standards), eg, interact with the Scientific writing team in the creation of preclinical PK/TK written and tabulated summaries for IND and BLA applications, as well as IBs, annual updates and other regulatory activities;
5. Provide leadership in the interactions with external collaborations （eg, CROs）;
6. Develop the capability strategy to ensure scientific excellence, quality of output and operational efficiency;
7. Drive continuous improvements to obtain operational efficiency and reliability in delivering results to projects;
8. Drive innovation in pharmacokinetics capability to meet discovery project unit’s medium and long term development goals;
9. Build the organization and people for sustainable project delivery and growth;
10. Contribute to Discovery Projects Unt’s overall strategy and management

Requirements（Qualification，Experience and Skills）

1. PhD in pharmacokinetics or pharmacodynamics or closely related filed;
2. Expertise and track record in PK and bioanalysis in drug discovery research will be essential;
3. Extensive experience in contributing and leading small molecule drug discovery projects will be required;
4. Approximately 5 or more years of relevant experiences in PK and bioanalysis experimental design, data collection and interpretation, especially the experience  gained in the research centers of major pharmaceutical , biotechnology companies or leading academic centers will be an advantage;
5. Excellent organizational, decision-making, inter-personal relations, and communication skills;
6. Ability to analyze and resolve problems in a timely manner;
7. Excellent verbal and written communication skills (Chinese and English);
8. Ability to work in a team environment with cross-functional interactions;

成都先导药物开发股份有限公司是由原阿斯利康全球化合物科学主任、计算科学总监、英国皇家化学学会会士李进博士创建的专业从事新药研发的生物技术公司。公司成立于2012年，注册资本3.6亿元，现位于成都天府国际生物城。2016年在美国成立全资子公司，首席科学家Barry Morgan博士曾任GSK分子发现部副总裁，同时也是推动DNA编码化合物库技术工业化的先驱。
成都先导的核心技术 “DNA编码化合物库技术”，是当前新药发现领域最前沿的技术之一，目前全球只有四家公司将该技术进行规模化应用。成都先导作为其中之一，是国内首家拥有该技术自主知识产权的企业，并对该技术做出了创造性的改革，弥补了其连接效率较低以及多样性不足的问题。该技术将帮助制药行业突破药物发展早期链端的研发瓶颈，为创新药研发行业带来突破性变革。
目前成都先导已建成分子结构超过4,000亿种的DNA编码小分子实体化合物库，成为中国***，全球多样性***的“新药种子库”，有望缩短新药发现周期2-3年，提高重大疾病疑难靶点的药物发现效率；具备每年超过50个物靶点的筛选能力；我们拥有近2万平米的国际标准实验室，配备完善的新药研发高端实验设备，科研环境优越。
成都先导拥有一支具备国际视野和创新能力的优秀团队，规模逾400人，博士学历占研发人员的15%以上，多位高级管理和研发人员具有跨国药企管理经验及知名科研机构研究背景。
目前公司正处于迅猛发展阶段：
成都先导药物开发股份有限公司是一家从事新药研发的快速发展的生物技术公司，总部位于中国成都，在美国设有子公司。成都先导（688222.SH）于2020年4月16日正式登陆资本市场，成为西南首家科创板上市企业。
成都先导为小分子新药发现建立了一个国际领先的，以DNA编码化合物库的设计、合成和筛选为核心的技术平台。目前，公司基于数百种不同的骨架结构，已经完成千亿级结构全新、具有多样性和类药性DNA编码化合物的合成，并且已有多个案例证实了其针对已知靶点和新兴靶点筛选苗头化合物的能力。
同时，成都先导建立了自己的新药研发管线，部分品种已进入临床实验阶段。成都先导业务遍布北美、欧洲及亚洲等，现已与多家国际著名制药公司、生物技术公司、化学公司、基金会以及科研机构建立合作，致力于新药的发现与应用。